Nom du produit:4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline
IUPAC Name:4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline
- CAS：2448173-20-2
- Formule moléculaire：C16H17N5O
- Pureté：95%+
- Numéro de catalogue：CM1045041
- Poids moléculaire：295.35
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2448173-20-2
- Formule moléculaire:C16H17N5O
- Point de fusion:-
- Code SMILES:NC1=CC=C(C=C1)C1=CC2=C(N=CN=C2N1)N1CCOCC1
- Densité:
- Numéro de catalogue:CM1045041
- Poids moléculaire:295.35
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Pyrrolopyrimidines
- Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.
Column Infos
- BMF-219
- Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.
Recherche 
+86 21 5895 0110 
